

FORM 9

NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES **(or securities convertible or exchangeable into listed securities)**

Please complete the following:

Name of CNSX Issuer: M Pharmaceutical Inc., formerly First Sahara Energy Inc. (the "Issuer").

Trading Symbol: MQ

Date: February 18, 2015.

Is this an updating or amending Notice: Yes No

If yes provide date(s) of prior Notices: n/a

Issued and Outstanding Securities of Issuer Prior to Issuance: 134,666,764

Date of News Release Announcing Private Placement: December 2, 2014.

Closing Market Price on Day Preceding the Issuance of the News Release: \$0.02

1. Private Placement (if shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition), proceed to Part 2 of this form) Not Applicable

1. Total amount of funds to be raised:

2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material.

3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer:

4. If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement to exchange the debt for securities.

5. Description of securities to be issued:
 - (a) Class :
 - (b) Number:
 - (c) Price per security:
 - (d) Voting rights:

6. Provide the following information if Warrants, (options) or other convertible securities are to be issued:
 - (a) Number:
 - (b) Number of securities eligible to be purchased on exercise of Warrants (or options):
 - (c) Exercise price:
 - (d) Expiry date:

7. Provide the following information if debt securities are to be issued:
 - (a) Aggregate principal amount _____ .
 - (b) Maturity date _____ .
 - (c) Interest rate _____ .
 - (d) Conversion terms _____ .
 - (e) Default provisions _____ .

8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.): Details are unknown at this time however a 10% commission may be paid to registrants with respect to all or a portion of the financing.
 - (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer):
 - (b) Cash:

- (c) Securities:
 - (d) Other:
 - (e) Expiry date of any options, warrants etc.
 - (f) Exercise price of any options, warrants etc.:
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship.
 10. Describe any unusual particulars of the transaction (i.e. tax “flow through” shares, etc.).
 11. State whether the private placement will result in a change of control.
 12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders.
 13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by Multilateral Instrument 45-102.

2. Acquisition -

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material:

The Company has signed an arms-length agreement to acquire and commercialize the rights to a biomedical device for the self-monitoring of blood glucose, primarily by diabetics. This device, called the eMosquito, is based on a novel in-plane actuator designed to provide minimally-invasive skin penetration to be used by persons with diabetes. The objective of the eMosquito is to obtain whole blood

samples by penetrating the skin to shallower depths and in less sensitive areas of the body. Persons with diabetes have traditionally used the "finger prick" method to monitor/test their blood glucose levels. The blood sample was obtained by pricking the finger tip, a highly sensitive area of the body. The eMosquito is envisioned to be worn like a patch with small needles designed to puncture the skin just deep enough to draw blood without affecting the nerve endings and causing little or no pain.

2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material:

Pursuant to a purchase and sale agreement dated February 18, 2015, the Company agreed to acquire all of the issued and outstanding shares of M Diagnostics Inc., a private company that holds all the technology rights to the eMosquito from Martin Mintchev, Orly Yadid-Pecht and James (Gang) Wang, all of Calgary, Alberta. This is an arms-length transaction - Dr. Mintchev joined the board after the transaction was agreed upon.

3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
 - (a) Total aggregate consideration in Canadian dollars: **approximately \$583,333 not including the royalty.**
 - (b) Cash: **US\$150,000**
 - (c) Securities (including options, warrants etc.) and dollar value: **8,066,670 at a deemed price of \$0.05 per share. These shares will be subject to an escrow that will see 10% of the shares releasable on closing, the balance in equal installments every 6 months over 3 years.**
 - (d) Other: **a 3% royalty on sales of products based on the technology**
 - (e) Expiry date of options, warrants, etc. if any: **n/a**
 - (f) Exercise price of options, warrants, etc. if any: **n/a**
 - (g) Work commitments: **n/a**
4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).

Arms-length

5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: n/a
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed by Party	Describe relationship to Issuer ⁽¹⁾
Martin P. Mintchev	2,688,890 common shares	\$0.05	n/a	NI45-106 S.2.21	2,688,890 common shares	Became a director after agreement
Orly Yadid-Pecht	2,688,890 common shares	\$0.05	n/a	NI45-106 S.2.21	2,688,890 common shares	none
Joseph (Gang) Wang	2,688,890 common shares	\$0.05	n/a	NI45-106 S.2.21	2,688,890 common shares	none

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: **basic patent and corporate due diligence**
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.): **Not Applicable**
 - (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer):
 - (b) Cash:
 - (c) Securities:
 - (d) Other:
 - (e) Expiry date of any options, warrants etc.
 - (f) Exercise price of any options, warrants etc.

9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. **n/a**
10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. **n/a**

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 9 Notice of Private Placement is true.

Dated February 18, 2015

D. Richard Skeith
Name of Director or Senior Officer

(signed) "Rick Skeith"
Signature

Director
Official Capacity